Company Description
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide.
The company’s principal products include Enbrel for the treatment of rheumatoid arthritis, plaque psoriasis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet’s disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.
It also markets other products, including PROLIA, REPATHA, OTEZLA, ENBREL, EVENITY, XGEVA, TEPEZZA, BLINCYTO, NPLATE, TEZSPIRE, KYPROLIS, ARANESP, KRYSTEXXA AND VECTIBIX, MVASI, PAVBLU, UPLIZNA, IMDELLTRA/IMDYLLTRA, AMJEVITA/AMGEVITA, TAVNEOS, NEULASTA, LUMAKRAS/LUMYKRAS, RAVICTI, PARSABIV, AIMOVIG, WEZLANA/WEZENLA, AND PROCYSBI.
The company serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies.
It distributes its products through pharmaceutical wholesale distributors. The company has collaboration agreements with AstraZeneca plc for the development and commercialization of TEZSPIRE; BEONE MEDICINES LTD.
to develop and commercialize Aimovig; UCB for the development and commercialization of EVENITY; Kyowa Kirin Co., Ltd. for rocatinlimab development and commercialization; and BeiGene, Ltd. for oncology products expansion and development.
The company was incorporated in 1980 and is headquartered in Thousand Oaks, California.
| Country | United States |
| Founded | 1980 |
| Industry | Drug Manufacturers - General |
| Sector | Healthcare |
| Employees | 31,500 |
| CEO | Robert Bradway |
Contact Details
Address: One Amgen Center Drive Thousand Oaks, California 91320-1799 United States | |
| Phone | 805 447 1000 |
| Website | amgen.com |
Stock Details
| Ticker Symbol | AMGN |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0000318154 |
| CUSIP Number | 031162100 |
| ISIN Number | US0311621009 |
| Employer ID | 95-3540776 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Robert A. Bradway | Chairman and Chief Executive Officer |
| Peter H. Griffith | Executive Vice President and Chief Financial Officer |
| Dr. David M. Reese M.D. | Executive Vice President and Chief Technology Officer |
| Murdo Gordon | Executive Vice President of Global Commercial Operations |
| Dr. James E. Bradner M.D. | Executive Vice President of Research and Development |
| Esteban Santos | Executive Vice President of Operations |
| Matthew C. Busch | Chief Accounting Officer and Vice President of Finance |
| Scott Skellenger | Senior Vice President and Chief Information Officer |
| Howard Y. Chang M.D., Ph.D. | Senior Vice President of Global Research and Chief Scientific Officer |
| Casey Capparelli | Executive Director of Investor Relations |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Feb 27, 2026 | 144 | Filing |
| Feb 24, 2026 | 25-NSE | Filing |
| Feb 19, 2026 | 8-K | Current Report |
| Feb 19, 2026 | 144 | Filing |
| Feb 19, 2026 | 424B2 | Prospectus |
| Feb 17, 2026 | FWP | Free Writing Prospectus |
| Feb 17, 2026 | 424B3 | Prospectus |
| Feb 13, 2026 | S-3ASR | Automatic shelf registration statement of securities of well-known seasoned issuers |
| Feb 13, 2026 | 10-K | Annual Report |
| Feb 3, 2026 | 8-K | Current Report |